Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2014-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2014.942728PMID 25060168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuroendocrine Neoplasms of the Pancreas

  2016cited by this paper
• Cabergoline treatment in acromegaly: cons

  2014cited by this paper
• Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis

  2014cited by this paper
• OR7-7: Pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: a phase III, multicenter, randomized study (PAOLA)

  2014cited by this paper
• Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

  2014cited by this paper
• Emerging drugs for acromegaly

  2014cited by this paper
• Cabergoline treatment in acromegaly: pros

  2014cited by this paper
• Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.

  2014cited by this paper
• Immune modulation in humans: implications for type 1 diabetes mellitus

  2014cited by this paper
• A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms

  2014cited by this paper
• Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

  2014cited by this paper
• Cabergoline treatment in acromegaly: pros

  2014cited by this paper
• Octreotide fluid crystal provides sustained octreotide bioavailability and similar IGF1 suppression to that of octreotide LAR (Sandostatin LAR): randomized, open-label, Phase I, repeat-dose study in healthy volunteers

  2014cited by this paper
• Vertebral fractures in patients with acromegaly: a 3-year prospective study.

  2013cited by this paper
• In vitro and in vivo evaluation of an in situ gel forming system for the delivery of PEGylated octreotide.

  2013cited by this paper
• Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.

  2013influential reference
• Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator.

  2013cited by this paper
• Improving the Success Rate of Gluteal Intramuscular Injections

  2013cited by this paper
• Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.

  2013cited by this paper
• Octreotide for acromegaly treatment: a reappraisal

  2013cited by this paper
• Investigational therapies for acromegaly

  2013cited by this paper
• A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

  2013cited by this paper
• Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

  2013cited by this paper
• Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

  2012cited by this paper
• A subcutaneous octreotide hydrogel implant for the treatment of acromegaly.

  2012cited by this paper
• DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.

  2012cited by this paper
• Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy

  2012cited by this paper
• Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

  2012cited by this paper
• PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

  2012cited by this paper
• A consensus on the diagnosis and treatment of acromegaly complications

  2012cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression.

  2012cited by this paper
• Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study

  2012cited by this paper
• Biotherapies for GEP-NETs.

  2012influential reference
• Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?

  2012cited by this paper
• ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

  2011cited by this paper
• Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

  2011cited by this paper
• Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.

  2011cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours

  2011cited by this paper
• Diabetes in Cushing syndrome: basic and clinical aspects.

  2011cited by this paper
• Clinical, quality of life, and economic value of acromegaly disease control

  2011cited by this paper
• Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas

  2011cited by this paper
• Current management practices for acromegaly: an international survey

  2011cited by this paper
• Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice.

  2011cited by this paper
• First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible

  2011cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors

  2011cited by this paper
• Treatment of Cushing disease: overview and recent findings

  2010cited by this paper
• Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

  2010cited by this paper
• Pituitary somatostatin receptor signaling.

  2010cited by this paper
• The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells.

  2010cited by this paper
• Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

  2010influential reference
• OR14,80 Octreolin™, a safe oral alternative for parenteral octreotide treatment

  2010cited by this paper
• Relationship Between Quality of Life and Health-Related Measures Including Symptoms, Biochemical Markers And Tumor Burden

  2010cited by this paper
• WHO Classification of Tumours of the Digestive System

  2010cited by this paper
• Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

  2010cited by this paper
• A consensus on criteria for cure of acromegaly.

  2010cited by this paper
• Somatostatin–dopamine ligands in the treatment of pituitary adenomas

  2009cited by this paper
• Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly

  2009cited by this paper
• Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

  2009cited by this paper
• Pancreatic somatostatinoma manifested as severe hypoglycemia.

  2009cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

  2009cited by this paper
• Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.

  2009cited by this paper
• Guidelines for acromegaly management: an update.

  2009cited by this paper
• High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.

  2009cited by this paper
• Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.

  2009cited by this paper
• Placebo-Controlled , Double-Blind , Prospective , Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors : A Report From the PROMID Study Group

  2009cited by this paper
• NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.

  2009cited by this paper
• Lung tumours with neuroendocrine differentiation.

  2009cited by this paper
• Gastroenteropancreatic neuroendocrine tumours.

  2008cited by this paper
• Pasireotide (SOM230): development, mechanism of action and potential applications.

  2008cited by this paper
• Emerging drugs for acromegaly

  2008influential reference
• AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.

  2007cited by this paper
• Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.

  2007cited by this paper
• Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis.

  2007cited by this paper
• Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2.

  2007cited by this paper
• A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation.

  2007cited by this paper
• The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly

  2007cited by this paper
• Gastroenteropancreatic endocrine tumors: clinical characterization before therapy

  2007cited by this paper
• Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.

  2007cited by this paper
• High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.

  2006cited by this paper
• Resistance to somatostatin analogs in acromegaly: An evolving concept?

  2006cited by this paper
• Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study.

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• Medical progress: Acromegaly.

  2006cited by this paper
• The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies.

  2006cited by this paper
• Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium

  2005cited by this paper
• Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross‐Sectional Study in Postmenopausal Women

  2005cited by this paper
• Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.

  2005cited by this paper
• BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.

  2005influential reference
• Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

  2005cited by this paper
• Somatostatin: a hormone for the heart?

  2005cited by this paper
• Consensus statement: medical management of acromegaly.

  2005cited by this paper
• Long‐Acting Octreotide and Prolonged‐Release Lanreotide Formulations Have Different Pharmacokinetic Profiles

  2005cited by this paper
• Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

  2004cited by this paper
• Factors influencing mortality in acromegaly.

  2004cited by this paper
• PTR-3173 (Somatoprim™), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion

  2004cited by this paper
• A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.

  2004cited by this paper
• The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.

  2004cited by this paper

• Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis

  2025cites this paper
• Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer

  2025cites this paper
• Diabetes mellitus in acromegaly: prevalence, pathophysiological particulars and treatment strategies

  2023cites this paper
• In silico screening of drug Bank data base to PDE10: A drug repurposing approach

  2023cites this paper
• Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

  2023cites this paper
• How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients

  2023cites this paper
• Secondary diabetes mellitus in acromegaly

  2023cites this paper
• Structural insights into ligand recognition and selectivity of somatostatin receptors

  2022cites this paper
• Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly

  2021cites this paper
• Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein

  2020cites this paper
• Should everolimus be stopped after radiological progression in metastatic insulinoma? A “cons” point of view

  2020cites this paper
• PASIREOTIDE FOR A PATIENT WITH ACROMEGALY AND CHRONIC KIDNEY DISEASE ON HEMODIALYSIS.

  2019cites this paper
• Somatostatin in renal physiology and autosomal dominant polycystic kidney disease

  2019cites this paper
• Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors.

  2019cites this paper
• Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies

  2019cites this paper
• IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug?

  2018cites this paper
• Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies

  2018influential citation
• Growth hormone deficiency in treated acromegaly and active Cushing's syndrome.

  2017cites this paper
• Pegvisomant in acromegaly: an update

  2017cites this paper
• Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells

  2017cites this paper
• Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects

  2017influential citation
• Glucose and lipid levels with lanreotide autogel 120 mg in treatment‐naïve patients with acromegaly: data from the PRIMARYS study

  2017cites this paper
• High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study

  2017influential citation
• Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials

  2016cites this paper
• The Modern Criteria for Medical Management of Acromegaly.

  2016cites this paper
• Pasireotide for the treatment of acromegaly

  2016cites this paper
• New medical therapies of acromegaly.

  2016cites this paper
• Current and Emerging Aspects of Diabetes Mellitus in Acromegaly.

  2016influential citation
• Current and future medical treatments for patients with acromegaly

  2016cites this paper
• New trends in guided nanotherapies for digestive cancers: A systematic review.

  2015cites this paper
• Growth hormone deficiency in treated acromegaly.

  2015cites this paper
• Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.

  2015cites this paper
• Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature

  2015cites this paper
• Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.

  2015cites this paper
• Towards model-based personalised medicine in oncology: using biomarkers to predict clinical outcome

  2015cites this paper